Concepedia

Publication | Open Access

First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer

DOIFull Paper Access

55

Citations

23

References

2020

Year

Lan Shen, Qiang Tan, Ziming Li, Ding Ding, Yongfeng Yu, Shun Lü
Cancer Medicine

Abstract

Our results suggested that first-line crizotinib had higher ORR and longer PFS than platinum-pemetrexed chemotherapy in patients with advanced ROS1+NSCLC, but the differences were not observed for OS.

References

YearCitations

Page 1